血浆或血清 TIMP-1 是结直肠癌生存结局的预测因子：一项荟萃分析。

Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis.

机构信息

Department of Pathology, Korea University Ansan Hospital, Ansan-Si, Republic of Korea.

出版信息

J Gastrointestin Liver Dis. 2011 Sep;20(3):287-91.

PMID:21961097

Abstract

BACKGROUND AND AIMS

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a small secretory glycoprotein with anti-apoptosis and anti-matrix metalloproteinase activity. There have been some discordant data regarding the value of TIMP-1 as a prognostic factor in colorectal cancer (CRC) patients. To address this controversy, we conducted a meta-analysis for the relationship between TIMP-1 levels and overall survival in CRC.

METHODS

We selected the relevant published studies using citation databases including PubMed, Science Citation Index, and Conference Papers Index. The effect sizes of TIMP-1 on the patient's overall survival and TNM stages were calculated by hazard ratio (HR) or odds ratio (OR), respectively. The effect sizes were combined using a random-effects model.

RESULTS

Survival outcomes between high and low plasma or serum TIMP-1 levels were compared by uni- and multivariate analyses involving 1,477 and 1,359 CRC patients, respectively. CRC patients with high plasma or serum TIMP-1 levels showed poor survival rates compared to patients with low plasma or serum TIMP-1 in the uni- and multivariate analyses (HR, 2.2 and 2.1; P < 0.001). In addition, high TIMP-1 expression in colon cancer tissues was significantly associated with worse survival outcomes in 438 CRC patients (HR = 1.4; P = 0.017).

CONCLUSION

Plasma or serum TIMP-1 levels predict survival outcomes of CRC patients.

摘要

背景与目的

组织金属蛋白酶抑制剂-1（TIMP-1）是一种具有抗细胞凋亡和抗基质金属蛋白酶活性的小分泌糖蛋白。关于 TIMP-1 作为结直肠癌（CRC）患者的预后因素的价值，存在一些不一致的数据。为了解决这一争议，我们进行了荟萃分析，以评估 TIMP-1 水平与 CRC 患者总生存率之间的关系。

方法

我们使用引文数据库（包括 PubMed、科学引文索引和会议论文索引）选择了相关的已发表研究。使用风险比（HR）或优势比（OR）分别计算 TIMP-1 对患者总生存率和 TNM 分期的效应大小。使用随机效应模型对效应大小进行合并。

结果

通过涉及 1477 例和 1359 例 CRC 患者的单变量和多变量分析，比较了高和低血浆或血清 TIMP-1 水平之间的生存结果。与低血浆或血清 TIMP-1 相比，高血浆或血清 TIMP-1 水平的 CRC 患者在单变量和多变量分析中均显示出较差的生存率（HR，2.2 和 2.1；P <0.001）。此外，在 438 例 CRC 患者中，结肠癌组织中高 TIMP-1 表达与更差的生存结局显著相关（HR=1.4；P=0.017）。